Innovative antibody-based therapies are advancing cancer treatment. Regeneron reported positive Phase III data for Libtayo, a PD-1 inhibitor, significantly reducing recurrence risks in high-risk cutaneous squamous cell carcinoma. New multispecific and bispecific antibodies are under investigation to enhance immune responses in cancers including triple-negative breast cancer. Muna Therapeutics patented TREM2 agonists targeting neurodegeneration and autoimmune diseases. Modulating immune checkpoints and revising tumor microenvironmental pathways remain critical focal points to overcome resistance and improve patient outcomes.